Primary hyperoxaluria type 1

The PBS subsidises lumasiran for patients with primary hyperoxaluria type 1.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lumasiran under the National Health Act 1953, section 85 for patients with primary hyperoxaluria type 1.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing lumasiran.

Treatment specifics

To be eligible for PBS-subsidised treatment with lumasiran, patients must be treated by or in consultation with either a:

  • nephrologist with experience in the management of hyperoxaluria
  • paediatrician with experience in the management of hyperoxaluria.

Authority applications

Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial authority approval to prescribe PBS-subsidised lumasiran to treat primary hyperoxaluria type 1 can be made:

All written applications must include:

Applying for initial grandfather treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial grandfather authority approval to prescribe PBS-subsidised lumasiran to treat primary hyperoxaluria type 1 can be made:

All written applications must include:

Applying for continuing treatment

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Applications for continuing authority approval to prescribe PBS-subsidised lumasiran to treat primary hyperoxaluria type 1 can be made in:

All written applications must include:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 October 2025.
QC 83181